{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-018867","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.337681+00:00","generated_at":"2026-05-15T04:16:23.705995+00:00","sec_items":["1.01","2.01","3.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1","bullets":["Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.","Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.","Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.","Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-018867","json":"https://secwatch.observer/filing/0001493152-26-018867.json","markdown":"https://secwatch.observer/filing/0001493152-26-018867.md","text":"https://secwatch.observer/filing/0001493152-26-018867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T04:16:23.705995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9412e679525e07021a2e6a470bdd1d4cfaddeb49","claim":"Telomir Pharmaceuticals, Inc. completed an acquisition involving TELI Pharmaceuticals, Inc. for 34,389,710 restricted shares of the Company’s common stock (closed 2026-04-22).","evidence_excerpt":"by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Company’s common stock, no par value issued to TELI’s former shareholders (the “Shares”). The number of shares issued was determined based on an exchange","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"TELI Pharmaceuticals, Inc."},{"label":"Consideration","value":"34,389,710 restricted shares of the Company’s common stock"},{"label":"Closing","value":"2026-04-22"}],"fact_type":"ma_transaction"},{"claim_id":"cc14c206cac4352bbd8fdb471a1f5db55b130336","claim":"Telomir Pharmaceuticals, Inc. entered into Commitment Agreement with Bayshore Trust (effective 2026-04-22).","evidence_excerpt":"On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226018867/0001493152-26-018867-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Bayshore Trust"},{"label":"Effective","value":"2026-04-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}